Thank you for subscribing!
Next Investors Feb 28, 2024
The market looks like it is rewarding the progress ONE made in 2023 laying the groundwork for a jump in growth during 2024.
Next Investors Mar 19, 2021
Last Friday we announced our 2021 Tech Pick of the Year, Oneview Healthcare plc (ASX: ONE) - a healthcare technology company that enables ‘virtual care’ at the bedside for hospital patients. We promised that we would provide further analysis on why we have made such a large, long term investment and called ONE our 2021 Tech Pick of the Year…
Finfeed Archived Jul 31, 2020
A deep re-imagining of how healthcare and patient care is delivered. This is being facilitated by Oneview Healthcare (ASX: ONE), an ASX-listed health-tech provider, which this year launched a cloud-based solution to help healthcare systems manage hospitalised patients during and after COVID-19.
Finfeed Archived Apr 14, 2020
Respiri Limited (ASX:RSH), an eHealth SaaS company supporting respiratory health management, signs a joint development venture agreement with Phenix Health Pty Ltd
Get expert stock analysis direct in your inbox
Finfeed Archived Apr 08, 2020
AVITA Medical Limited (ASX: AVH) is a med-tech stock worth targeting outside the blue chips such as ResMed, CSL and Ramsay Health Care.
Finfeed Archived Mar 25, 2020
Lifespot Health Limited (ASX: LSH) Bodytel® System already has the capability to track blood sugar, ECG, blood pressure and weight via the existing Bluetooth connected devices.
Finfeed Archived Mar 18, 2020
OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.
Finfeed Archived Feb 27, 2020
The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.
Next Investors Archived Jan 30, 2020
OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.
Finfeed Archived Dec 04, 2019
Medical technology company, HeraMED Limited (ASX:HMD) is pursuing verification around the potential for its HeraBEAT and HeraCARE solutions to be reimbursed under the US reimbursement code system.
Finfeed Archived Dec 02, 2019
Medical technology group HeraMED Limited (ASX:HMD) has gone from strength to strength, excelling in the area of product development and distribution, but also forging alliances with other global, high profile medical institutions.
Finfeed Archived Nov 26, 2019
Advent Energy, in which BPH Energy (ASX:BPH) has a 25% interest, had previously interpreted significant seismically indicating gas features indicating hydrocarbon accumulation following a review in 2004.
Next Investors Archived Nov 21, 2019
HeraMED (ASX:HMD) has signed an agreement with Kinderheldin to add online midwifery service to be offered as HeraBEAT PLUS in Germany.
Finfeed Archived Nov 19, 2019
Streamlining of the group’s internal operations and the pending Progenza licensing deal in Japan, will see Regeneus sufficiently funded to commercialisation in Japan.
Finfeed Archived Nov 18, 2019
With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.
Medical technology company, HeraMED Limited’s (ASX:HMD) 510(k) application (K191110) for the company’s HeraBEAT US foetal ultrasonic heart rate monitor (HeraBEAT US) has been cleared by the US Food and Drug Administration (FDA).
Finfeed Archived Nov 14, 2019
Medical technology group HeraMED Limited (ASX:HMD) has gone from strength to strength since listing on the ASX in December 2018.
Next Investors Archived Nov 14, 2019
HeraMED (ASX:HMD) has a target market of 2 million pregnancies in 2020, 6 million in 2021 and 45 million in 2022.
Join Our Mailing List
